synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
GLP requires not only that the methods of safety tests be transparent, but that they be so detailed that a different laboratory using it will get the same result. Considering that Japan, Netherlands, US and others had at same time as GLP begun requiring demonstrations of safety before chemicals gained access markets; the Organisation for Economic Cooperation & Development decided that multinational companies needed globally uniform regulation of chemicals, such that a toxicity test performed in one country could be accepted by another. OECD was thus happy to add the new USA GLP requirement into their new, globally-required test methods, called ‘OECD Test Guidelines’ (see below OECD section).
Such an inflexible dosing regime limits the utility benzodiazepines offer in practice; e.g. lorazepam and alprazolam can be used as needed for situational anxiety in which continuous use is unnecessary or excessive, while clonazepam can be titrated to response when continuous relief is indicated, up to a maximum of 4 mg a day, four times greater than the dose used in comparison with etifoxine over the 24 week duration of the trial. In general, they offer a degree of personalization that is not possible with etifoxine. Indeed, better evidence is required before etifoxine can be said to replace benzodiazepines in practice, especially considering the trials above were relatively small in size, along with the high attrition rates and lack of personalization of the benzodiazepines used. The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). It is taken for a few days to a few weeks, but no longer than 12 weeks.
An opioidergic agent (or drug) is a chemical which directly or indirectly modulate the function of opioid receptors. Opioidergics comprise opioids, as well as allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.
=== Capsule === The capsule consists of 20-70 concentrically-arranged connective tissue lamellae around the axon terminal at its center, forming a structure much like an onion. The capsule consists of fibroblasts and fibrous connective tissue (mainly Type IV and Type II collagen network), separated by gelatinous material, more than 92% of which is water. It presents a whorled pattern on micrographs. If the corpuscle's capsule is experimentally removed, the divested axon terminal becomes slowly adapting. The capsule is therefore responsible for the corpuscle's selectivity for high-frequency stimuli. This is a result of the slippery lamellae sliding past each other when the corpuscle is structurally deformed by external pressure so that effects of sustained pressure are soon dissipated by the lamellae, abolishing deformation of the central axon terminal itself. The capsule thus acts as a physiological high-pass filter.
Sources: en.wikipedia.org
Among the earliest reports of MOF-based catalysis was the cyanosilylation of aldehydes by a 2D MOF (layered square grids) of formula Cd(4,4′-bpy)2(NO3)2. This investigation centered mainly on size- and shape-selective clathration. A second set of examples was based on a two-dimensional, square-grid MOF containing single Pd(II) ions as nodes and 2-hydroxypyrimidinolates as struts. Despite initial coordinative saturation, the palladium centers in this MOF catalyze alcohol oxidation, olefin hydrogenation, and Suzuki C–C coupling. At a minimum, these reactions necessarily entail redox oscillations of the metal nodes between Pd(II) and Pd(0) intermediates accompanying by drastic changes in coordination number, which would certainly lead to destabilization and potential destruction of the original framework if all the Pd centers are catalytically active. The observation of substrate shape- and size-selectivity implies that the catalytic reactions are heterogeneous and are indeed occurring within the MOF. Nevertheless, at least for hydrogenation, it is difficult to rule out the possibility that catalysis is occurring at the surface of MOF-encapsulated palladium clusters/nanoparticles (i.e., partial decomposition sites) or defect sites, rather than at transiently labile, but otherwise intact, single-atom MOF nodes. "Opportunistic" MOF-based catalysis has been described for the cubic compound, MOF-5.
AAS is calculated as mg of limiting amino acid in 1 g of test protein / mg of same amino acid in 1 g of reference protein. FTPD is calculated as PI - (FP - MFP)/PI. PI is protein intake, FP is fecal protein, MFP is metabolic fecal protein (amount of protein in feces on a protein-free diet). The digestibility test is done with rats. Some sources may list AAS and PD separately as percentages.
{\displaystyle {\begin{aligned}\mathrm {length} (ab)&={\sqrt {\left(dx+{\frac {\partial u_{x}}{\partial x}}dx\right)^{2}+\left({\frac {\partial u_{y}}{\partial x}}dx\right)^{2}}}\\&={\sqrt {dx^{2}\left(1+{\frac {\partial u_{x}}{\partial x}}\right)^{2}+dx^{2}\left({\frac {\partial u_{y}}{\partial x}}\right)^{2}}}\\&=dx~{\sqrt {\left(1+{\frac {\partial u_{x}}{\partial x}}\right)^{2}+\left({\frac {\partial u_{y}}{\partial x}}\right)^{2}}}\end{aligned}}}
The 2021 Canadian census enumerated a total population of 36,991,981, an increase of around 5.2 percent over the 2016 figure. It is estimated that Canada's population surpassed 40,000,000 in 2023. The main drivers of population growth are immigration and, to a lesser extent, natural growth. Canada has one of the highest per-capita immigration rates in the world, driven mainly by economic policy and family reunification. A record 483,390 immigrants were admitted in 2024. Canada leads the world in refugee resettlement; it resettled more than 47,600 in 2022. New immigrants settle mostly in major urban areas, such as Toronto, Montreal, and Vancouver. Canada's population density, at 4.2 inhabitants per square kilometre (11/sq mi), is among the lowest in the world, with approximately 95 percent of the population residing south of the 55th parallel north. About 80 percent of the population lives within 150 kilometres (93 mi) of the border with the contiguous United States. Canada is highly urbanized, with over 80 percent of the population living in urban centres. The majority of Canadians (over 70%) live south of the 49th parallel, with 50 percent of Canadians living south of 45°42′ (45.7 degrees) north. The most densely populated part of the country is the Quebec City–Windsor Corridor in Southern Quebec and Southern Ontario along the Great Lakes and the St. Lawrence River. The majority of Canadians (81.1%) live in family households, 12.1 percent report living alone, and 6.8 percent live with other relatives or unrelated persons.
In 1953, he married American actress and singer Gloria DeHaven. They divorced in 1954. His second marriage was to Claudia Aronow, a New York artist and daughter of boat designer and racer Donald Aronow. They later divorced. They had one son together, menswear designer Adam Kimmel who is married to the actress Leelee Sobieski. His third marriage was to Helen Lyttle. In addition, Kimmel has several stepchildren: stepdaughter Betsy Karel of Washington; stepdaughter Abby Leigh of Manhattan; and stepson Alexei Hay of Manhattan. Kimmel was a member of Temple Emanu-El in New York City. Kimmel died April 15, 2008. In November 2008, his wife Helen donated $150 million toward construction of a new patient pavilion at the NYU Langone Medical Center in honor of her late husband.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.